Chromosome aneuploidies commonly arise in embryos produced by assisted reproductive technologies and represent a major cause of implantation failure and miscarriage. Currently, preimplantation genetic diagnosis (PGD) is performed by arraybased methods to identify euploid embryos for transfer to the patient. We speculated that a combination of next-generation sequencing technologies and sophisticated bioinformatics would deliver a more comprehensive and accurate methodology to improve the overall efficacy of embryo testing. To meet this challenge, we developed a high-resolution copy number variation (CNV) sequencing pipeline suitable for single-cell analysis. In validation studies, we showed that CNV-Seq was highly sensitive and specific for detection of euploidy, aneuploidy, and segmental imbalances in 24 whole genome amplification samples from PGD embryos that were originally diagnosed by gold standard array comparative genomic hybridization. In addition, CNV-Seq was capable of detecting, mapping, and accurately quantifying terminal chromosome imbalances down to 1 Mb in size originating from abnormal segregation of translocation chromosomes. These validation studies indicate that CNV-Seq displays the hallmarks of an accurate and reliable embryo test with the potential to further improve the overall efficacy of PGD.
INTRODUCTION
Since the first successful demonstration of preimplantation genetic diagnosis (PGD) for X-linked disease using PCR analysis of single biopsied blastomeres for the male-specific gene SRY [1] , there has been rapid development and implementation of different molecular technologies for the identification of chromosomal abnormalities that are commonly associated with in vitro fertilization (IVF) embryos [2] . Single-cell fluorescent in situ hybridization (FISH) was initially developed for preimplantation genetic screening to detect aneuploidy for chromosomes 13, 16, 18, 21, 22 , X, and Y that are most often commonly associated with spontaneous abortions [3] . In addition, for PGD of translocations, chromosome-specific centromeric and telomeric probes were designed to distinguish balanced from unbalanced embryos produced by translocation carriers, leading to a reduction in spontaneous abortions [4] . The limitations of FISH to simultaneously analyze all 24 chromosomes was first solved by the development of whole genome amplification (WGA) methods such as degenerate oligonucleotide primer PCR [5] in conjunction with single-cell metaphase comparative genomic hybridization (CGH) [6] . More recently, the development and clinical implementation of alternative diagnostic technologies such as array CGH [7] , single nucleotide polymorphism (SNP) arrays [8, 9] , and multiplex quantitative fluorescent-PCR [10] has facilitated widespread testing of embryos for aneuploidy and structural abnormalities that can involve any of the 24 chromosomes.
FISH analysis of gametes and embryos from PGD cycles [3, 11] has shown that whole chromosome aneuploidies originating from meiotic I and II errors and postfertilization mitotic errors are common, leading to either embryonic growth arrest, implantation failure, or spontaneous miscarriage in the early first trimester. More recently, detailed molecular analyses of cleavage-stage embryos using array-based methods [12, 13] have shown the occurrence of other types of chromosomal aberrations, including segmental duplications and deletions, as well as other more complex structural abnormalities, demonstrating the inherent instability of human embryonic chromosomes [14] . In clinical practice, array CGH and SNP arrays generally exhibit high reliability and accuracy for detection of gross chromosomal abnormalities. However, based on the currently available commercial array platforms, there are significant differences in probe design, probe customization, and chromosome probe density distributions, and, combined with the potential occurrence of random allelic dropout, the resolution may not be sufficient on some platforms to detect all types of clinically significant chromosomal aberrations in IVF embryos. In addition, in regard to SNP arrays, there is a limitation in calling trisomies and other duplications that originate without meiotic recombination [2] . Further, from biopsy to report, array work flows are tedious, requiring DNA labeling and a long hybridization step. Moreover, array slides and reagents are moderately expensive, and the test is difficult to scale efficiently due to limitations in the number of arrays printed per slide. The advent of next-generation sequencing (NGS), combined with powerful bioinformatics algorithms to analyze large data sets of mapped sequencing data, opens up new opportunities in PGD to develop a more comprehensive and cost-effective single platform technology for the diagnosis of the full spectrum of chromosomal abnormalities that randomly occur in IVF embryos.
The feasibility of NGS for chromosome analysis of oocyte polar bodies [15] , blastomeres [16, 17] , and blastocyst trophectoderm biopsies [18] has recently been demonstrated. However, these methodologies do not adequately incorporate critical features, such as high resolution at low sequencing depth and accurate quantitation of copy number, that are paramount for comprehensive and accurate chromosome analysis of embryo biopsy samples. To approach this problem, we initially developed a copy number variation sequencing (CNV-Seq) pipeline based on validated whole genome sequencing and bioinformatics methodologies that we currently use for noninvasive prenatal diagnosis of fetal aneuploidies [19] . In subsequent studies, we reported the successful application of CNV-Seq for measurement of maternal mosaicism in white blood cells down to 5% [20] , for determining the degree and nature of confined placental mosaicism in placental biopsy samples [21, 22] , and, more recently, for assessing whole chromosome aneuploidy in single cells [16] .
In the study reported here, CNV-Seq was specifically modified for the analysis of embryo biopsy samples by first introducing a reliable PCR-based WGA step into the sequencing pipeline to generate sufficient DNA template for molecular analysis and then applying more sophisticated data analysis algorithms to determine the mean CNV sequentially along the length of each chromosome. In retrospective and blind validation studies, we assessed the performance of CNVSeq on WGA products from single embryonic blastomeres with chromosome aneuploidies previously detected using a wellestablished standard array CGH methodology and demonstrated a high diagnostic concordance between the two techniques.
MATERIALS AND METHODS

Study Design
Clinical PGD was conducted at three sites: the Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, with approval from the Ethics Committee of the Chinese PLA General Hospital (S2013-092-02); the Tangdu Hospital IVF Center, Fourth Military Medical University, Xi'an, with approval from the Ethics Committee of Tangdu Hospital; and the State Key Laboratory of Reproductive Medicine, Nanjing Medical University, under the requirements specified by a PGD license. Patients provided written informed consent before undertaking PGD by array CGH. In addition, consent was also provided for research using the surplus WGA products from their embryo biopsy samples to test other diagnostic technologies, such as NGS to confirm array CGH results. For clinical validation of CNV-Seq, WGA products from embryos previously diagnosed as either aneuploid or euploid by BlueGnome array CGH were selected for analysis, including 10 samples in a retrospective study and 14 samples in a blind study.
In Vitro Fertilization, Embryo Biopsy, and Cryopreservation IVF and embryo biopsy procedures were performed at the Department of Obstetrics and Gynecology, Chinese PLA General Hospital, Beijing, and at the Tangdu Hospital, Fourth Military Medical University, Xi'an, using previously published procedures [23] . In brief, fertilization of MII oocytes was achieved by intracytoplasmic sperm injection to avoid surplus sperm contamination. Following sperm injection (Day 0), MII oocytes were incubated in G1 medium (Vitrolife), and fertilization was assessed after 15-18 h by the presence of two pronuclei. One cell embryos were washed and then individually placed in a single drop of G1 media (Vitrolife) under mineral oil in a four-well dish placed in a 5% CO 2 incubator. Embryos were cultured for 48 h to the cleavage stage, transferred to G2 medium, and incubated 48-72 h for development to the blastocyst stage. For cleavage-stage biopsy, embryos were placed into 20 ll of G-MOPS medium (Vitrolife) under mineral oil, and a hole was created using a noncontact laser (Saturn Research Instruments Ltd). One blastomere from each embryo was removed by micromanipulation using a finely pulled glass pipette. For blastocyst biopsy, five to eight trophectoderm cells herniating from the hole in the zona pellicuda created by the laser at Day 3 were biopsied from expanding blastocysts using a rubbing dissecting method. Biopsied cell(s) were washed in PBS and transferred to a PCR tube containing 2-4 ll of sterile PBS. Clinical IVF and embryo biopsy was also performed at the State Key Laboratory of Reproductive Medicine, Nanjing Medical University, using similar procedures [24] .
Biopsied embryos were cryopreserved by vitrification at the blastocyst stage. All solutions used during vitrification and thawing were prepared according to the manufacturer's protocol (Kitazato Supply). Embryos were first equilibrated in equilibration solution for 5 min at room temperature followed by incubation for 5 min in vitrification solution. Embryos were then loaded into a MVC plate (Cryotop; Kitazato Supply) and immediately plunged into liquid nitrogen. Frozen embryos diagnosed as euploid following PGD were thawed by immersing the MVC plate directly into thawing solution at 378C for 1 min. Recovered embryos were transferred to a diluent solution and held for 3 min, after which they were incubated for 10 min in the washing solution. Thawed embryos were further cultured for 2 h, and then one to two embryos were placed in an embryo catheter and transferred to the women's uterus for implantation.
Preimplantation Genetic Diagnosis
Following embryos biopsy, single blastomeres or trophectoderm cells were washed three times in PBS, carefully transferred by micromanipulation into 2.5 ll of PBS placed in the bottom of a 200-ll PCR tube, and then frozen at À208C. Biopsied blastomeres and/or trophectoderm cells as well as PBS blank controls were subjected to WGA amplification (PicoPLEX Kit). A 5-ll aliquot of the 50-ll WGA reaction was analyzed on a 1.5% ethidium bromide agarose gel to verify the quality and size distribution of the PCR fragments. The two criteria for WGA products to pass quality control before proceeding to the library construction step were an average size of 300 base pairs (bp; range 100-500 bp) and a concentration of .50 ng/ll for a single blastomere and .100 ng/ll for a trophectoderm biopsy sample. For array CGH, reference and test DNA samples were labeled with Cy5 and Cy3, respectively, and embryo aneuploidy testing was performed by array CGH using 24sure V2 or V3 arrays (BlueGnome) according to a standard protocol [7] .
CNV Sequencing and Data Analysis
WGA products were purified through DNA clean and concentrator Zymo columns (Zymo Research) to remove unincorporated primers and then resuspended at a concentration of 50 ng/ll. Sequencing libraries containing a terminal sequencing primer and a 9-bp bar code were prepared from 50 ng of WGA product as previously described [19, 25] and then subjected to sequencing on the HiSeq 2500 Illumina platform to generate approximately 5 million 36-bp single end reads, representing a 0.06-fold genome coverage. Sequencing reads were collated and aligned to the unmasked genome using the Burrows-Wheeler algorithm [26] . Approximately 3 million uniquely mapped reads were then further allocated to sequential 20K sequencing bins (average 30 sequencing reads per bin). A minimum of 15 test samples from the same sequencing run were internally compared with each other as reference using the data processing and analysis algorithms described previously [20] . The mean CNV across sequential 20K bins along the entire length of each chromosome was determined by applying the global smooth copy number algorithm CGHseq [27, 28] allowing quantitation of each CNV.
CNV-Seq profiles for all 24 chromosomes were presented as log 2 values of the mean sequencing read number per 20K bin (Y-axis) versus sequential 20K sequencing bins from the p arm to the q arm (X-axis). Red bars on the plots mark regions of repetitive sequences, and the black bar marks the centromere. A dashed line at (log 2 [3/2] ) highlights the position of a 100% chromosome gain (duplication), and a dashed line at (log 2 [1/2] ) highlights the position of a 100% chromosome loss (deletion). The mean CNV along the length of each chromosome was traced with a blue line, allowing quantitation and precise mapping of regions of CNV relative to the hg19 reference genome.
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RESULTS
Validation of CNV-Seq for Detection of Aneuploidy
The performance of CNV-Seq was benchmarked against BlueGnome BAC array CGH, which is an accepted gold standard diagnostic technology currently used for PGD of chromosomal abnormalities in IVF embryos [7] . At the Tangdu Hospital PGD Laboratory, PGD was performed using array CGH as the primary diagnostic method for patients with a poor prognosis for pregnancy. In the first validation study of CNVSeq, we selected eight WGA products from aneuploid embryos and two WGA products from transferred euploid embryos that had previously produced healthy term babies. Following the CNV-Seq analysis on these 10 WGA products, there was a 100% concordance with the original array CGH diagnosis for the eight aneuploid embryos and the two euploid embryos (Table 1) . Two examples of concordant array CGH and CNVSeq diagnosis are shown for an embryo with monosomy 2 ( 
Validation of CNV-Seq for Detection of Unbalanced Translocations
In a second validation study, where PGD was also performed by BlueGnome BAC array CGH at the Clinical Center of Reproductive Medicine PGD Laboratory, First Affiliated Hospital, Nanjing Medical University, 14 embryo WGA products selected from 12 different PGD translocation cases were blinded and sent for CNV-Seq analysis. Following CNV-Seq analysis, samples were unblinded and results compared to the original array CGH results (Table 1 WANG ET AL.
ANEUPLOIDY ASSESSMENT OF IVF EMBRYOS BY SEQUENCING
chromosome profile). In the one discordant case, involving a t(8;18)(q21;q23) reciprocal translocation where the breakpoint on Chr18 was located very close to the q arm terminus, the embryo was provisionally diagnosed as normal by array CGH, although an unbalanced translocation was suspected (Fig. 3) . However, CNV-Seq provided a definitive diagnosis of two chromosomal imbalances, clearly detecting a 34-Mb 8p-qter duplication and the 0.9-Mb 18-qter deletion as well as an additional 7.9-Mb Xp terminal deletion. In the remaining four embryo samples, CNV-Seq correctly detected an unbalanced Robertsonian translocation, a simple and a complex aneuploidy, and, importantly, the only euploid embryo sample that was included in the blind study (Table 1 ). In summary, the overall concordance between the two diagnostic methods in the blind study of translocations was 13 of 14 (93%), with array CGH missing a pair of unbalanced translocation chromosomes and a 7.9-Mb Xp deletion in the one discordant embryo.
DISCUSSION
In this study, we have developed and validated a single-cell NGS technology called CNV-Seq specifically for PGD of chromosome abnormalities in IVF embryos. The performance of CNV-Seq was tested in a retrospective and blinded validation study by directly comparing array CGH and CNVSeq diagnoses on the same WGA products derived from single ANEUPLOIDY ASSESSMENT OF IVF EMBRYOS BY SEQUENCING embryonic blastomeres. Overall, CNV-Seq correctly diagnosed 3 of 3 euploid embryos, 12 of 12 embryos with whole or partial chromosome aneuploidies, and 9 of 10 embryos with different size segmental imbalances caused by mis-segregation of a parental translocation. For the single discordant result, CNVSeq was able to confirm an imbalance of Chr8 and Chr18 in an embryo that was provisionally called euploid by array CGH. In addition, CNV-Seq also correctly diagnosed the sex of all the 25 embryos. On the basis of these validation studies, we conclude that CNV-Seq performs similarly to BlueGnome array CGH for detection of whole and partial chromosome aneuploidies as well as terminal imbalances generated from mis-segregation of translocation chromosomes. Still, before CNV-Seq can be implemented into routine clinical PGD, FIG. 3 . CNV-Seq embryo diagnosis of an unbalanced t(8;18)(p21;q23) translocation missed by array CGH. The array CGH diagnosis was euploid, although an unbalanced translocation was suspected (relevant diagnostic probes are circled in red). Conversely, CNV-Seq clearly detected a 34-Mb 8p-qter duplication and a 0.9-Mb 18-qter deletion resulting from adjacent 1 segregation of the t(8;18)(p21;q13) translocation at meiosis 1. In addition, CNVSeq detected an incidental 7.9-Mb Xp terminal deletion.
further validation studies on a larger number of embryo samples is warranted to determine its sensitivity and specificity.
We previously reported a low-coverage NGS method that analyzed changes in the representation of the mapped chromosome sequencing reads of test compared to reference samples, allowing the accurate diagnosis of whole chromosome aneuploidy [16] . In this study, we were able to increase the resolution of our previous method by incorporating more sophisticated bioinformatics algorithms that divided and progressively analyzed sequencing reads from smaller chromosome segments, allowing identification of CNV. This higher resolution incorporated into CNV-Seq for embryo analysis was specifically achieved by allocating the approximately 3 M uniquely mapped reads randomly produced by low-coverage sequencing to 20-kb sequential bin sizes (approximately 30 sequencing reads per bin) along the length of each chromosome, thus maximizing the use of all the sequencing reads in data analysis. In essence, this represents approximately 150 000 data points for 24-chromsome analysis, which is 50-fold higher than the 3000 BlueGnome array probes that can provide an average genome resolution of only approximately 1 Mb [7] . Thus, by comparison, CNV-Seq has the capacity to provide a high and relatively even resolution across all 24 chromosomes with the exception of highly repetitive regions associated with the Y chromosome and the p arms of the acrocentric chromosomes and, in addition, can more accurately map CNV intervals relative to the hg19 reference genome [26] . This higher resolution, at similar sequencing depth, therefore enabled us to extend chromosome diagnosis using CNV-Seq from whole chromosome aneuploidies [16] to small segmental imbalances and CNVs.
These new diagnostic features of CNV-Seq were exemplified by the detection of a 0.9-Mb deletion at the termini of Chr8 representing an unbalanced product of the reciprocal translocation t(8;18)(q21;q23). This small CNV of 0.9 Mb could be confidently defined by the cumulative mean sequencing reads of 45 consecutive bins, with the corresponding CNV endpoints defined 620 kb. In a recent validation study of 200 WGA embryo samples using a similar NGS pipeline to CNV-Seq [17] , high sensitivity and specificity for euploidy and aneuploidy was also achieved with only one false positive reported for trisomy 18. In this study [17] , CNV analysis was performed by allocating sequencing reads to 1-Mb sequencing bins, enabling the detection of duplications down to 14, 17, and 20 Mb in size. Nonetheless, we argue that the use of larger 1-Mb sequencing bins effectively loses valuable resolution, and thus accurate and reproducible detection of smaller clinically significant CNVs in embryos may not be possible with their current data analysis algorithms.
Importantly, in the one discordant embryo associated with the t(8;18)(q21;q23) translocation patient, CNV-Seq was able to provide a clear diagnosis of two chromosome imbalances and detect an incidental Xp deletion that was completely missed by array CGH. Review of the corresponding array CGH plot for this embryo revealed significant background hybridization noise for a significant number of the chromosome probes, which we believe was the result of a suboptimal WGA reaction causing high levels of genome amplification bias. However, the greater resolution of CNV-Seq achieved through a much higher density of sequencing reads was able to overcome any local effects of the genome bias that is exacerbated in suboptimal WGA reactions [29, 30] and provide a definitive diagnosis of this embryo.
Another superior feature of CNV-Seq compared to the recently published NGS method [17] was the ability to more accurately quantitate chromosome copy number change. In our study, the copy number of all confirmed embryo duplications and deletion intervals fell well within 20% of the theoretical values of 3 and 1, respectively. The proficiency of CNV-Seq to precisely map accurately small CNVs with the correct copy number potentially expands its clinical utility beyond aneuploidy to the detection of chromosome disease syndromes and some single gene diseases that are known to be caused by small deletion events [31] . In this scenario, any small CNVs identified by CNV-Seq could then be simply mapped down to a resolution of a 20-kb sequencing bin, allowing further interrogation of the corresponding region on the hg19 reference genome to identify the loss or gain of genes associated with a disease syndrome. Further, the ability of CNV-Seq to also quantify the correct dosage of ChrX and ChrY will be particularly important to improve the diagnostic accuracy of sex chromosome aneuploidies in embryos that are sometimes problematic using array-based hybridization methods [2, 32] . Moreover, with the increasing use of trophectoderm biopsy for clinical PGD [8, 10, 33] where the presence of mosaicism can occur [34] , it will be paramount to use a technology like CNVSeq to differentiate normal from low to moderate levels of mosaicism and reduce the possibility of a misdiagnosis.
At a practical level, while arrays have proven to be very reliable and accurate for PGD [2, 35] , work flow is long and tedious (up to 24 h), and the array slides and associated reagents for DNA labeling and hybridization are relatively expensive. In addition, arrays are not easily scalable since the number of samples on any given day can fall short or exceed the maximum number of arrays per slide. In contrast, for a busy PGD laboratory, CNV-Seq offers several potential advantages over arrays. First, CNV-Seq has simple work flow from WGA of the embryo biopsy sample to a final embryo diagnosis, and, using the Illumina HiSeq2500 sequencing platform, analysis can be completed in approximately 16 h, allowing the option of a fresh embryo transfer. Second, the method is scalable from 1 to 100 samples, allowing batching of daily samples. Third, based on reagent costs for WGA, library construction and operation of the Hi-Seq 2500 Illumina sequencing platform, and ensuring that the flow cells are run at maximum capacity with other diagnostic samples, each embryo sample can be analyzed at a 2-to 5-fold lower cost compared to an embryo analyzed on the different array platforms currently used for PGD. Fourth, in our hands, the standard operating procedure for CNV-Seq involves minimal tube transfers, and, with the incorporation of a bar code into all the sequence reads for each sample, the potential for human error and thus misdiagnosis is significantly reduced. Finally, with the cost of sequencing reagents expected to continually fall over time, NGS technologies like CNV-Seq should be become very affordable not only for the PGD laboratory but also for the patient if the cost savings are passed on to the end user.
In conclusion, based on the high performance of CNV-Seq in this study combined with two other recently reported embryo validation studies using similar methodologies, [17, 18] , NGSbased technologies are rapidly evolving as a viable alternative to array CGH and SNP arrays for PGD of chromosomal abnormalities. With the option of deeper sequencing, it may also be possible to expand the clinical utility of our CNV-Seq method beyond aneuploidy testing to reliable and accurate detection of small CNVs associated with known chromosomal disease syndromes [36] . Importantly, the overall cost-effectiveness offered by NGS-based technologies in terms of reduced work flow, labor, and reagents will undoubtedly increase the overall efficiency of PGD in the laboratory and ultimately allow more patients access to PGD treatment. At the ANEUPLOIDY ASSESSMENT OF IVF EMBRYOS BY SEQUENCING
